Xun Yang1, Ying Huang2, Ji-Feng Feng1. 1. Department of Thoracic Surgery, Zhejiang Cancer Hospital No. 38 Guangji Road, Banshan Bridge, Hangzhou 310022, China. 2. Department of Operating Theatre, Zhejiang Cancer Hospital No. 38 Guangji Road, Banshan Bridge, Hangzhou 310022, China.
Abstract
BACKGROUND: The relationship between ABO blood group and clinical characteristics had been studied in several cancers. However, its role in esophageal cancer (EC) is unclear. The aim of this study was to determine whether ABO blood group is associated with overall survival in patients with esophageal squamous cell carcinoma (ESCC). METHODS: From 2005 to 2008, a retrospective analysis of 496 consecutive patients with ESCC was conducted. The relationship between ABO blood group and clinicopathologic features of ESCC was analyzed. Prognostic factors for overall survival of ESCC were also analyzed. RESULTS: The 5-year overall survival of ESCC patients with blood group A, B, AB and O were 47.8%, 44.1%, 43.2%, and 38.4%, respectively (P = 0.165). However, patients with blood group non-O have a better 5-year overall survival than patients with blood group O (45.7% vs. 38.4%; P = 0.043). Multivariate analyses showed ABO blood group (O vs. non-O; P = 0.034) is an independent prognostic factors. CONCLUSIONS: ABO blood group is associated with overall survival in patients with ESCC. We concluded that patients with blood group O have a significantly worse overall survival than non-O blood groups.
BACKGROUND: The relationship between ABO blood group and clinical characteristics had been studied in several cancers. However, its role in esophageal cancer (EC) is unclear. The aim of this study was to determine whether ABO blood group is associated with overall survival in patients with esophageal squamous cell carcinoma (ESCC). METHODS: From 2005 to 2008, a retrospective analysis of 496 consecutive patients with ESCC was conducted. The relationship between ABO blood group and clinicopathologic features of ESCC was analyzed. Prognostic factors for overall survival of ESCC were also analyzed. RESULTS: The 5-year overall survival of ESCC patients with blood group A, B, AB and O were 47.8%, 44.1%, 43.2%, and 38.4%, respectively (P = 0.165). However, patients with blood group non-O have a better 5-year overall survival than patients with blood group O (45.7% vs. 38.4%; P = 0.043). Multivariate analyses showed ABO blood group (O vs. non-O; P = 0.034) is an independent prognostic factors. CONCLUSIONS:ABO blood group is associated with overall survival in patients with ESCC. We concluded that patients with blood group O have a significantly worse overall survival than non-O blood groups.
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Simona Iodice; Patrick Maisonneuve; Edoardo Botteri; Maria Teresa Sandri; Albert B Lowenfels Journal: Eur J Cancer Date: 2010-12 Impact factor: 9.162
Authors: Brian M Wolpin; Andrew T Chan; Patricia Hartge; Stephen J Chanock; Peter Kraft; David J Hunter; Edward L Giovannucci; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2009-03-10 Impact factor: 13.506
Authors: Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Nasser K Altorki; Ermanno Ancona; S Michael Griffin; Arnulf Hölscher; Toni Lerut; Simon Law; Thomas W Rice; Alberto Ruol; Jan J B van Lanschot; John Wong; Tom R DeMeester Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Céline Montavon Sartorius; Andreas Schoetzau; Henriette Kettelhack; Daniel Fink; Neville F Hacker; André Fedier; Francis Jacob; Viola Heinzelmann-Schwarz Journal: PLoS One Date: 2018-03-29 Impact factor: 3.240